CBD Acts as a Systemic Immunometabolic Modulator, Not Just an Anti-Inflammatory
CBD reduces key inflammatory cytokines and triggers major liver gene reprogramming in a dose- and time-dependent pattern in male mice.
Summary
Researchers gave healthy male mice cannabidiol (CBD) by injection at three doses for either 2 days or 28 days. Blood levels of three key inflammatory signals fell with CBD: IL-1β and TNF-α dropped within 2 days, and IL-6 dropped later, by up to about 45% at the higher doses after 28 days. The liver changed far more than the spleen. At the highest dose, hundreds of liver genes shifted, touching energy production, fat metabolism, the body clock and innate immunity. The spleen showed only small gene changes. The authors conclude that CBD acts more like a metabolic and immune modulator than a simple immune suppressant. This was a mouse study with injected doses, so it does not show the same effects in people.
Detailed Summary
Chronic low-grade inflammation is a driver of age-related disease, and CBD is widely used for its reputed anti-inflammatory effects. Yet few studies have linked circulating inflammatory markers to what CBD does inside specific organs. This study asked how CBD's effects on blood cytokines compare with its effects on gene activity in the liver, the main site of CBD metabolism, and the spleen, a central immune organ.
The team used 48 male C57BL/6J mice aged 60 days. Animals received daily intraperitoneal CBD at 0.2, 10 or 20 mg/kg, or vehicle, for 2 days (short-term) or 28 days (long-term), with 6 mice per group. IL-1β, IL-6 and TNF-α were measured by ELISA at day 2, day 14 and day 28. RNA sequencing was run on liver and spleen, and a subset of liver genes was checked by qPCR.
Cytokine effects depended on the cytokine and the timing. After 2 days, IL-1β fell from 69.7 to 49.0 pg/mL at the top dose (about 18–30% across doses, p<0.001). TNF-α fell from 107.9 to 59.1 pg/mL (about 20–45%, p<0.001). IL-6 did not change at that point. At day 14, IL-6 fell about 16–26% (p<0.01). By day 28, IL-6 was down about 40–45% at 10 and 20 mg/kg (45.3 to roughly 27–28 pg/mL, p<0.001), and TNF-α was modestly lower (about 12%, p<0.01).
The liver responded strongly. After 2 days, 0.2, 10 and 20 mg/kg altered 116, 11 and 526 genes, and 469 of the 526 (89%) at the top dose were upregulated. Those genes were enriched for mitochondrial respiration, ribosome biogenesis and translation. After 28 days, 104 to 404 genes changed depending on dose. Lipid and fatty acid metabolism were enriched at the lowest dose and circadian-clock genes at 20 mg/kg. Innate immune and interleukin-1 signaling were enriched among upregulated genes, and glucose metabolism among downregulated genes.
The spleen barely changed. Short-term 20 mg/kg altered 40 genes, 38 of them downregulated, with a trend toward lipid-related processes. Long-term treatment altered only 2 to 4 genes, and principal component analysis showed no separation between groups. In the liver, qPCR agreed with RNA-seq for most genes (r=0.69–0.90), though Ighg2b correlated poorly (r=0.316).
The authors propose that CBD works as an immunometabolic modulator, not a blanket immunosuppressant. Lower cytokines coexisted with liver activation of innate immune and mitochondrial programs. Important caveats apply. The mice were healthy and male, dosing was by injection, and the study did not test whether these changes improve any health outcome, so human relevance is unproven.
Key Findings
- Short-term CBD (2 days) cut serum IL-1β from 69.68 to 49.04 pg/mL at 20 mg/kg, an 18–30% reduction across doses (p<0.001)
- TNF-α fell about 20–45% after 2 days (107.91 to 59.12 pg/mL at 20 mg/kg, p<0.001), and was still about 12% lower at day 28 (p<0.01)
- IL-6 was unchanged at 2 days but fell 16–26% at day 14 (p<0.01) and 40–45% at day 28 with 10 and 20 mg/kg (45.27 to ~27 pg/mL, p<0.001)
- Liver gene expression changed in a dose-dependent way: 116, 11 and 526 genes at 0.2, 10 and 20 mg/kg after 2 days, with 89% of the 526 upregulated at the top dose
- Long-term liver changes (104–404 genes) pointed to lipid and fatty acid metabolism, circadian clock genes at 20 mg/kg, and upregulated innate immune and IL-1 signaling
- The spleen changed little: 40 genes (38 downregulated) after short-term 20 mg/kg and only 2–4 genes after 28 days, with no group separation on PCA
- qPCR validation of liver RNA-seq showed good concordance (r=0.69–0.90), though Ighg2b was poor (r=0.316)
Methodology
Forty-eight 60-day-old male C57BL/6J mice were randomized to short-term (2 days) or long-term (28 days) daily intraperitoneal CBD at 0.2, 10 or 20 mg/kg, or vehicle (saline with 2% Tween 80), with n=6 per group. IL-1β, IL-6 and TNF-α were measured by ELISA at day 2, 14 and 28; small-volume samples were sometimes pooled, with at least 3 replicates per group. Liver and spleen RNA were sequenced (Illumina NovaSeq 6000; different library kits for each organ), analyzed with DESeq2 and GO enrichment (FDR<0.05, fold change >2), and 24 liver samples were checked by qPCR. Cytokines were analyzed by ANOVA with Tukey post-hoc testing.
Study Limitations
The study used only healthy young male mice, injected CBD intraperitoneally (not oral dosing), and did not challenge the animals with an inflammatory stimulus, so clinical relevance is limited. Sample sizes were small (n=6), some samples were pooled or excluded as outliers, and liver and spleen used different sequencing methods, which complicates comparison. No functional or histological outcomes, or tissue CBD levels, were reported. The conflict-of-interest statement was not included in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: